Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer

Inclusion Criteria:

• 1. age: 18-70 years old, female;

2. patients with primary breast cancer, T2 or above, diagnosed by histopathology;

3. HR was positive and HER-2 was negative by IHC;

4. according to the RECIST 1.1 standard, there should be at least one measurableobjective focus with tumor diameter > 2cm;

5. ECoG physical fitness score 0-1;

6. LVEF≥55%；

7. bone marrow function: neutrophil ≥ 1.5 × 109 / L, platelet ≥ 100 × 109 / L,hemoglobin ≥ 90g / L;

8. liver and kidney function: serum creatinine ≤ 1.5 times the upper limit of normalvalue; AST and alt ≤ 2.5 times the upper limit of normal value; total bilirubin ≤ 1.5times the upper limit of normal value, or patients with Gilbert's syndrome ≤ 2.5 timesthe upper limit of normal value;

9. patients have good compliance with the planned treatment, can understand theresearch process of this study and sign the written informed consent

Exclusion Criteria:

• 1. previously received cytotoxic chemotherapy, endocrine therapy, biological therapyor radiotherapy for any reason;

2. patients with stage IV metastasis at the initial diagnosis;

3. New York Heart Association (NYHA) rating of patients with heart disease above gradeII (including grade II);

4. patients with serious systemic infection or other serious diseases;

5. patients who are known to be allergic or intolerant to chemotherapy drugs or theiradjuvants;

6. in the past 5 years, there have been other malignant tumors, except the curedcarcinoma in situ of cervix and skin cancer without melanoma;

7. pregnancy or lactation, as well as childbearing age patients who refuse to takeappropriate contraceptive measures during the trial;

8. participated in other experimental studies within 30 days before the administrationof the first study drug;

9. patients not suitable for the study were judged by the researchers.